Revenue: Reported $19.93 million for Q1 2024, slightly below the estimate of $22.22 million.
Net Loss: Posted a net loss of $6.63 million for Q1 2024, exceeding the estimated loss of $4.86 million.
Earnings Per Share (EPS): Recorded a loss of $0.15 per share, slightly higher than the estimated loss of $0.14 per share.
Gross Margin: Maintained a consistent gross margin around 89%, closely aligned with the previous years 90%.
U.S. DANYELZA Net Product Revenues: Increased by 11% year-over-year to $18.6 million, driven by higher demand across new and existing accounts.
Research and Development Expenses: Slightly decreased by 1% to $13.3 million, reflecting a balance between reduced personnel costs and increased clinical trial expenses.
Cash Position: Ended the quarter with $75.7 million in cash and cash equivalents, expected to support operations into 2027.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.